

# Molecular Therapeutics of Cancer Research Conference -- 2020

Sponsored by the Cancer Molecular Therapeutics Research Association

## Skamania Lodge at the Columbia River Gorge, Stevenson, Washington

### Schedule and Program

*IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers*

- All scientific sessions will be in .....
- Breaks, Poster sessions with refreshments will be in .....
- The opening reception Sunday evening will be in .....
- The Farewell Reception will be in .....
- **\*\*Lodging will be at the Skamania Lodge\*\***

#### SUNDAY – JULY 19

4:00 pm	Arrival and check-in (Lobby)
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 7:45 pm	<b>Welcome / Introductory Comments</b> Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX, President CMTRA
7:45 – 9:45 pm	<b>KEYNOTE SPEAKER(s)</b>  “Match Trials: What Have They Accomplished?” Ian F. Tannock CM, MD, PhD, DSc Emeritus Professor of Medical Oncology, Princess Margaret Cancer Centre
10:00 pm –	<i>Opening reception</i>

#### MONDAY – JULY 20

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	<b>MORNING SESSION: Phosphatases Inhibitors</b> Discussion Leaders: Eli Wallace, BridgeBio and John Lazo, U. Virginia
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	“Targeting oncogenic phosphatases in cancer—the example of SHP2” Peter Hammerman, Novartis
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break

10:00 – 10:30 am	“Activity of RMC-4630, a selective allosteric inhibitor of the phosphatase SHP2, in KRAS mutant Non-Small Cell Lung Cancer” Revolution Medicines
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	“Protein Phosphatase 2A – lessons from small molecules, tumor mutants and DNA tumor viruses” Goutham Narla, M.D., Ph.D. Associate Professor, University of Michigan, Medical School
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:45 pm	<b>OPEN NETWORKING AFTERNOON—(Activities Handout)</b>
5:00 – 6:30 pm	<b>Poster Session and Social</b>
6:30 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	<b>EVENING SESSION: Intersection of Immunotherapy with DNA damage</b>  Discussion Leader: Bob Abraham
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	“DNA damage and the antitumor immune response” Roger Greenberger, U. Penn
8:15 – 8:45 pm	Discussion
8:45 – 9:15 pm	“Targeting oncogenic-induced replication stress” Thanos Halazonetis. University of Geneva
9:15 – 9:45 pm	Discussion
9:45 pm –	<i>Social</i>

## TUESDAY – JULY 21

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	<b>MORNING SESSION: RAF Beyond BRAF</b> Discussion Leader: Shiva Malek
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	“Discovery and development of a next-generation BRAF inhibitor” Gideon Bollag (Plexxicon)
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i><b>Group Picture</b> and Coffee Break</i>
10:00 – 10:30 am	“New insights into oncogenic RAS mutants and RAS post translational modifications” Sharon Campbell (UNC)
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	“Following MAPK pathway in cancer patients-from clinical trials to real world data” Yibing Yan (Genentech)
11:30 – 12:00 pm	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:45 pm	<b>OPEN NETWORKING AFTERNOON</b>
5:00 – 6:30 pm	<b>Poster Session and Social</b>
6:30 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	<b>EVENING SESSION: Developing Title</b> Discussion Leader: Mary-Ann Bjornsti
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	TBA
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	TBA
9:15 – 9:40 pm	Discussion
9:40 pm –	<i>Social (Location)</i>

## WEDNESDAY – JULY 22

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	<b>MORNING SESSION: Advances in the Treatment of Breast Cancer</b>  Discussion Leader: Lori Friedman
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	“TBA” Ciara Metcalfe (Genentech)
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	“Development of Tucatinib, a Brain-Penetrant HER2 Inhibitor, for Patients with HER2-Positive Metastatic Breast Cancer” Virginia Borges (University of Colorado)
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	TBA
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
2:00 – 3:00 pm	<b>ORAL PRESENTATIONS – Four Selected Presenters from the Posters</b>
3:00 – 5:30 pm	<b>AFTERNOON SESSION: Single cell analysis – what is it teaching us?</b>  Discussion Leader: Pete Houghton
3:00 – 3:15 pm	Introduction
3:15 – 3:45 pm	“Therapeutic implications of single-cell analysis” Tim Huang, UT Health San Antonio
3:45 – 4:10 pm	Discussion
4:10 – 4:40 pm	TBA
4:45 – 5:10 pm	Discussion
6:00 – 10:00 pm	<b><i>Farewell Reception</i></b>

## THURSDAY – JULY 23

7:30 – 8:15 am	<i>Breakfast</i>
11:00 am	CHECK OUT BY 11:00 AM

THIS MEETING WOULD NOT BE POSSIBLE WITHOUT THE GENEROUS CONTRIBUTIONS  
FROM OUR MANY FRIENDS AND COLLEAGUES:

**TBA**

MOLECULAR THERAPEUTICS OF CANCER 2021

**TBA**